Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P49
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -7.48% |
| Q3 2025 | 126.64% |
| Q2 2025 | -143.43% |
| Q1 2025 | 336.17% |
| Q4 2024 | 0.49% |
| Q3 2024 | 7.91% |
| Q2 2024 | -39.58% |
| Q1 2024 | 7.58% |
| Q4 2023 | -26.05% |
| Q3 2023 | -5.48% |
| Q2 2023 | -313.23% |
| Q1 2023 | 214.31% |
| Q4 2022 | 49.74% |
| Q3 2022 | -14.98% |
| Q2 2022 | -275.46% |
| Q1 2022 | 165.62% |
| Q4 2021 | 2.41% |
| Q3 2021 | -103.60% |
| Q2 2021 | -12.88% |
| Q1 2021 | -17.37% |
| Q4 2020 | 52.01% |
| Q3 2020 | -214.31% |
| Q2 2020 | 28.30% |
| Q1 2020 | -358.27% |
| Q4 2019 | -150.35% |
| Q3 2019 | -48.17% |
| Q2 2019 | -15.51% |
| Q1 2019 | 101.08% |
| Q4 2018 | 198.00% |
| Q3 2018 | 29.84% |
| Q2 2018 | -5.89% |
| Q1 2018 | -8.84% |
| Q4 2017 | -34.76% |
| Q3 2017 | -79.38% |
| Q2 2017 | 6.78% |
| Q1 2017 | 58.87% |
| Q4 2016 | 31.63% |
| Q3 2016 | -12.69% |
| Q2 2016 | 9.04% |
| Q1 2016 | -9.95% |